BioStock: Xintela signs agreement with CRO for phase I/II study

Biopharma company Xintela continues to take important steps towards its first clinical trial with the drug candidate XSTEM-OA. This spring, the company was granted permission to produce cell therapy products in its own GMP facility and has now signed an agreement with the Australian CRO GreenLight Clinical to conduct the first clinical trial in humans with the candidate.

Read the full interview with Evy Lundgren-Åkerlund at biostock.se:

https://www.biostock.se/en/xintela-signs-agreement-with-cro-for-phase-i-ii-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se